Results 111 to 120 of about 35,270 (248)

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1760-1770, June 2026.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon, Hinke Huisman‐Siebinga, Shelby Barnett, Paul Wetherell, Pamela Kearns, Brenda Gibson, Nicholas Heaney, Owen Smith, André Baruchel, Arnaud Petit, Andrew Moore, Kayode Ogungbenro, Alwin D. R. Huitema, Gareth J. Veal   +13 more
wiley   +1 more source

The acute oncologist’s role in managing patients with cancer and other comorbidities

, 2012
Background: An Acute Oncology Service (AOS) is paramount to providing timely and improved pathways of care for patients who are admitted to hospital with cancer-related problems or suspected cancer.
James Price, Danson , S.J., Kate Shankland, Peter Kirkbride, Kirkbride, Peter, Walkington, Lucy, Shankland, Kate, Price, J., Danson, Sarah, Kirkbride, P., Sarah Danson, Price, James, Bourke, Anne-Marie, Shankland, K., Lucy Walkington, Walkington, L., Anne-Marie Bourke   +16 more
core   +1 more source

Malignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse

Cancer Medicine, Volume 15, Issue 6, June 2026.
BLURB FOR ETOC: Patients presenting with advanced MOGCT can be offered fertility‐sparing surgery after neoadjuvant chemotherapy with no detriment in oncological outcome. ABSTRACT Background Malignant ovarian germ cell tumors [MOGCT] are rare cancers affecting young women and often present in advanced stages.
Sayak Dey, Srikant Anne, Sushmita Rath, Ravindra Nandhana, Seema Gulia, Biswajit Dash, Santosh Menon, Bharat Rekhi, Akshay Baheti, Nilesh Sable, Palak Popat, Sandeep Tandon, Kinjalka Ghosh, Lavanya Gurram, Sarika Shivram Parab, Apenla N. Logkumer, Sunita Jhadhav, Supriya Chopra, Shylasree T. Surappa, Vandana Bansal, Geeta Balsarkar, Kedar Deodhar, Amita Maheshwari, Jaya Ghosh, Sudeep Gupta   +24 more
wiley   +1 more source

Febrile Neutropenia

, 2018
Sistemsko zdravljenje solidnih in hematoloških rakov s citostatiki predstavlja tveganje za različne neželene učinke. Febrilna nevtropenija (FN) je eno od urgentnih stanj v onkologiji, ker lahko pride do zapletov, kot sta septični šok ali sindrom dihalne ...
Pajk, Bojana, Jezeršek Novaković, Barbara   +1 more
core   +2 more sources

Febrile neutropenia in haematological malignancies [PDF]

, 2006
Fever is the principle sign of infection in neutropenic patient and frequently may be the only evidence of infection. The pattern of fever in neutropenia is non-specific and not pathognomonic of any type of infections or non-infectious process and can be
Sharma A, Lokeshwar N
core  

Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background Total neoadjuvant therapy (TNT) is the standard treatment for locally advanced rectal cancer (LARC). Few studies have focused on the toxicity of TNT. Moreover, the differences in safety and tolerability between radiotherapy‐first and chemotherapy‐first strategies remain unclear.
Shohei Udagawa, Hiroki Osumi, Senzo Taguchi, Tatsuki Noguchi, Takashi Sakamoto, Shimpei Matsui, Toshiki Mukai, Tomohiro Yamaguchi, Shota Fukuoka, Koichiro Yoshino, Keitaro Shimozaki, Takeru Wakatsuki, Mariko Ogura, Akira Ooki, Keisho Chin, Kensei Yamaguchi, Takashi Akiyoshi, Eiji Shinozaki   +17 more
wiley   +1 more source

Febrile Neutropenia in Intensive Care Unit

Southwest Respiratory and Critical Care Chronicles, 2015
Febrile neutropenia is a serious complication of cancer treatment and causes significant morbidity and mortality, especially when these patients present with sepsis or septic shock requiring intensive care unit admission.
Nattamol Hosiriluck, Saba Radhi
doaj  

Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH

Hematology, Transfusion and Cell Therapy
Febrile neutropenia is a major complication of the treatment of patients with hematologic diseases. Recent epidemiologic changes, with an increase in infection caused by drug-resistant bacteria, represent a major challenge for the proper management of ...
Marcio Nucci, Celso Arrais-Rodrigues, Maria Daniela Bergamasco, Marcia Garnica, Ana Beatriz Firmato Gloria, Mariana Guarana, Clarisse Machado, Jessica Ramos, Marco Aurelio Salvino, Belinda Simões   +9 more
doaj   +1 more source

[Prognostic factors for febrile neutropenia]

, 2006
International audienceCytotoxic chemotherapy suppresses the haematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated.
Bachelot, Thomas, Guastalla, Jean-Paul, Ray-Coquard, Isabelle, Biron, Pierre, Borg, Christophe, Ghesquière, Hervé, Fayette, Jérome, Sebban, Catherine, Blay, Jean-Yves, Marec-Bérard, Perrine, Zufferey, Laura   +10 more
core  

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
In a real‐world matched cohort study of treatment‐naïve TP53 wild‐type CLL patients, venetoclax plus obinutuzumab demonstrated significantly longer time to next treatment and improved 4‐year overall survival compared to first‐line acalabrutinib. Despite higher rates of cytopenias and infections, the venetoclax‐based regimen showed superior efficacy ...
Po‐Wei Liao, Bor‐Sheng Ko, Yu‐Chen Su, Wei‐Ting Chao, Chieh‐Lin Jerry Teng   +4 more
wiley   +1 more source